234 related articles for article (PubMed ID: 24781826)
1. Dengue: challenges for policy makers and vaccine developers.
Wilder-Smith A; Macary P
Curr Infect Dis Rep; 2014 May; 16(5):404. PubMed ID: 24781826
[TBL] [Abstract][Full Text] [Related]
2. [Dengue fever: from disease to vaccination].
Teyssou R
Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
[TBL] [Abstract][Full Text] [Related]
3. Dengue vaccines: challenges, development, current status and prospects.
Ghosh A; Dar L
Indian J Med Microbiol; 2015; 33(1):3-15. PubMed ID: 25559995
[TBL] [Abstract][Full Text] [Related]
4. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
[TBL] [Abstract][Full Text] [Related]
5. Immunoinformatics design of a novel epitope-based vaccine candidate against dengue virus.
Fadaka AO; Sibuyi NRS; Martin DR; Goboza M; Klein A; Madiehe AM; Meyer M
Sci Rep; 2021 Oct; 11(1):19707. PubMed ID: 34611250
[TBL] [Abstract][Full Text] [Related]
6. Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes.
Lecouturier V; Berry C; Saulnier A; Naville S; Manin C; Girerd-Chambaz Y; Crowe JE; Jackson N; Guy B
Vaccine; 2019 Jul; 37(32):4601-4609. PubMed ID: 29706291
[TBL] [Abstract][Full Text] [Related]
7. Working towards dengue as a vaccine-preventable disease: challenges and opportunities.
Shrivastava A; Tripathi NK; Dash PK; Parida M
Expert Opin Biol Ther; 2017 Oct; 17(10):1193-1199. PubMed ID: 28707486
[TBL] [Abstract][Full Text] [Related]
8. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.
Weiskopf D; Angelo MA; Bangs DJ; Sidney J; Paul S; Peters B; de Silva AD; Lindow JC; Diehl SA; Whitehead S; Durbin A; Kirkpatrick B; Sette A
J Virol; 2015 Jan; 89(1):120-8. PubMed ID: 25320311
[TBL] [Abstract][Full Text] [Related]
9. Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates.
Sundaram AK; Ewing D; Blevins M; Liang Z; Sink S; Lassan J; Raviprakash K; Defang G; Williams M; Porter KR; Sanders JW
Vaccine; 2020 Apr; 38(17):3313-3320. PubMed ID: 32184032
[TBL] [Abstract][Full Text] [Related]
10. Review of dengue virus and the development of a vaccine.
Murrell S; Wu SC; Butler M
Biotechnol Adv; 2011; 29(2):239-47. PubMed ID: 21146601
[TBL] [Abstract][Full Text] [Related]
11. Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines.
Hou J; Ye W; Chen J
Front Immunol; 2022; 13():840104. PubMed ID: 35281026
[TBL] [Abstract][Full Text] [Related]
12. Vaccines licensed and in clinical trials for the prevention of dengue.
Torresi J; Ebert G; Pellegrini M
Hum Vaccin Immunother; 2017 May; 13(5):1059-1072. PubMed ID: 28281864
[TBL] [Abstract][Full Text] [Related]
13. Dengue Vaccines: Ongoing Challenges and Current Status in the Advancement of Different Candidates.
Hassan M; Hassan A; Farooq M; Afzal S; Khan MA; Amin I; Shahid M; Idrees M; Shahid AA
Crit Rev Eukaryot Gene Expr; 2021; 31(5):7-19. PubMed ID: 34591385
[TBL] [Abstract][Full Text] [Related]
14. Well-balanced immune response and protective efficacy induced by a single dose of live attenuated tetravalent dengue vaccine (KD-382) in monkeys.
Yoshimura M; Shinmura Y; Takagi S; Kameyama K; Sonoda K; Koide F; Yoksan S; Kimachi K
Heliyon; 2020 Jul; 6(7):e04506. PubMed ID: 32760828
[TBL] [Abstract][Full Text] [Related]
15. Targets and strategies for vaccine development against dengue viruses.
Wang WH; Urbina AN; Lin CY; Yang ZS; Assavalapsakul W; Thitithanyanont A; Lu PL; Chen YH; Wang SF
Biomed Pharmacother; 2021 Dec; 144():112304. PubMed ID: 34634560
[TBL] [Abstract][Full Text] [Related]
16. Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate.
Swanstrom JA; Henein S; Plante JA; Yount BL; Widman DG; Gallichotte EN; Dean HJ; Osorio JE; Partidos CD; de Silva AM; Baric RS
J Infect Dis; 2018 May; 217(12):1932-1941. PubMed ID: 29800370
[TBL] [Abstract][Full Text] [Related]
17. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
[TBL] [Abstract][Full Text] [Related]
18. Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine.
Lim HX; Lim J; Poh CL
Med Microbiol Immunol; 2021 Feb; 210(1):1-11. PubMed ID: 33515283
[TBL] [Abstract][Full Text] [Related]
19. Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.
Martinez DR; Metz SW; Baric RS
Cell Host Microbe; 2021 Jan; 29(1):13-22. PubMed ID: 33444553
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
